Literature DB >> 8413627

Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.

J Parma1, L Duprez, J Van Sande, P Cochaux, C Gervy, J Mockel, J Dumont, G Vassart.   

Abstract

The pituitary hormone thyrotropin stimulates the function, expression of differentiation and growth of thyrocytes by cyclic AMP-dependent mechanisms. Tissue hyperplasia and hyperthyroidism are therefore expected to result when activation of the adenylyl cyclase-cAMP cascade is unregulated. This is observed in several situations, including when somatic mutations impair the GTPase activity of the G protein Gsa (ref 6, 7). Such a mechanism is probably responsible for the development of a minority of monoclonal hyperfunctioning thyroid adenomas. Here we identify somatic mutations in the carboxy-terminal portion of the third cytoplasmic loop of the thyrotropin receptor in three out of eleven hyperfunctioning thyroid adenomas. These mutations are restricted to tumour tissue and involve two different residues (aspartic acid at position 619 to glycine in two cases, and alanine at position 623 to isoleucine in one case). The mutant receptors confer constitutive activation of adenylyl cyclase when tested by transfection in COS cells. This shows that G-protein-coupled receptors are susceptible to constitutive activation by spontaneous somatic mutations and may thus behave as proto-oncogenes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8413627     DOI: 10.1038/365649a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  129 in total

1.  Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay.

Authors:  C Parnot; S Bardin; S Miserey-Lenkei; D Guedin; P Corvol; E Clauser
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  Thyrotropin receptor mutations in thyroid diseases.

Authors:  P M Yen
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

Review 3.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

4.  Calcium-induced activation of a mutant G-protein-coupled receptor causes in vitro transformation of NIH/3T3 cells.

Authors:  A O Hoff; G J Cote; H A Fritsche; H Qiu; P N Schultz; R F Gagel
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

Review 5.  The PTH/PTHrP receptor in Jansen's metaphyseal chondrodysplasia.

Authors:  L M Calvi; E Schipani
Journal:  J Endocrinol Invest       Date:  2000-09       Impact factor: 4.256

Review 6.  New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.

Authors:  J K L Walker; R B Penn; N A Hanania; B F Dickey; R A Bond
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

7.  Mutation of Pro-258 in transmembrane domain 6 constitutively activates the G protein-coupled alpha-factor receptor.

Authors:  J B Konopka; S M Margarit; P Dube
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

8.  Gating function of isoleucine-116 in TM-3 (position III:16/3.40) for the activity state of the CC-chemokine receptor 5 (CCR5).

Authors:  A Steen; A H Sparre-Ulrich; S Thiele; D Guo; T M Frimurer; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

9.  An in vivo screening system to identify tumorigenic genes.

Authors:  T Ihara; Y Hosokawa; K Kumazawa; K Ishikawa; J Fujimoto; M Yamamoto; T Muramkami; N Goshima; E Ito; S Watanabe; K Semba
Journal:  Oncogene       Date:  2016-10-03       Impact factor: 9.867

10.  A monoclonal antibody with thyrotropin (TSH) receptor inverse agonist and TSH antagonist activities binds to the receptor hinge region as well as to the leucine-rich domain.

Authors:  Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  Endocrinology       Date:  2009-03-19       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.